New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity. As such, it is imperative to identify novel alternatives that are better tolerated but equally or mor...
Alternative Titles
Full title
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2669d17c00f048fb9977a6e613b8ad20
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2669d17c00f048fb9977a6e613b8ad20
Other Identifiers
ISSN
1999-4923
E-ISSN
1999-4923
DOI
10.3390/pharmaceutics16060818
